论文部分内容阅读
本研究通过体外细胞培养技术初步确定黄芪甲苷(Astragaloside IV,AST)抑制甲型流感病毒(Influenza A virus,IAV)H1N1亚型和呼吸道合胞病毒(Respiratory syncytial virus,RSV)的生物学活性,以确定黄芪甲苷对RSV和IAV的抗病毒作用。使用5~100μg/m L的AST,在不影响细胞活性的情况下作用HEP-2细胞和A549细胞,观察48 h,检测AST对RSV、IAV的抑制作用。结果发现,AST对RSV无明显抑制作用,而在40~100μg/m L安全剂量下,AST对IAV在A549细胞增殖有显著抑制作用。采集感染后12 h细胞样品,real-time RT-PCR检测IL-1?、IL-6和TNF-αm RNA的相对表达量,结果显示,用药组的细胞因子转录水平均明显低于感染组。这提示黄芪甲苷对甲型流感病毒具有一定的抗病毒作用。
In this study, the biological activity of Astragaloside IV (AST) in inhibiting H1N1 subtype and respiratory syncytial virus (RSV) of Influenza A virus (IAV) To determine the antiviral effect of Astragaloside on RSV and IAV. HEP-2 cells and A549 cells were treated with 5 ~ 100 μg / mL of AST without affecting the cell viability. The inhibitory effect of AST on RSV and IAV was observed 48 h after treatment. The results showed that, AST had no significant inhibitory effect on RSV, and safe dose of 40 ~ 100μg / m L, AST on IAV in A549 cell proliferation was significantly inhibited. The expression of IL-1|Á, IL-6 and TNF-|ÁmRNA were detected by real-time RT-PCR at 12 h after infection. The results showed that the transcription level of cytokines in the treated group was significantly lower than that in the infected group. This suggests that astragaloside IV influenza A virus has a certain antiviral effect.